Brief: Basilea Receives USD 39 Mln Funding
July 8 (Reuters) - BASILEA PHARMACEUTICA AG ALLSCHWIL BSLN.S: RECEIVES USD 39 MILLION FUNDING UNDER BARDA AGREEMENT TO CONTINUE TO ADVANCE NOVEL ANTIFUNGALS FOSMANOGEPIX AND BAL2062 Source text: ID:nGNX69STGF Further company coverage: BSLN.S (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Basilea Pharmaceutica AG, Allschwil
See all newsBrief: Basilea Pharmaceutica - Strong Cresemba Sales In Europe Trigger USD 37.5 Mln Milestone Payment
Basilea seen up after raising 2026 guidance
Brief: Basilea Expects 2026 Operating Profit Of CHF 115 Mln
Brief: Basilea Reports Presentation Of New Data For Fosmanogepix, Isavuconazole And Ceftobiprole At IDWeek 2026
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments